Squamous cell carcinoma of the maxillary sinus: A population‐based analysis

Dubal, Pariket M.; Bhojwani, Amit; Patel, Tapan D.; Zuckerman, Omry; Baredes, Soly; Liu, James K.; Eloy, Jean Anderson

doi:10.1002/lary.25601

Cited by 62 publications

(61 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Due to the relative rarity of MS‐SCC, no randomized prospective studies have been performed . Although Kim et al report a 13.5% risk of occult metastasis in patients who did not receive END at the time of primary resection, Dubal et al demonstrate that the risk could be as high as 22.2% in MS‐SCC, which would meet the criteria for the employment of END . Additionally, Le et al report a 20% 60‐month nodal relapse rate in patients without elective neck control versus 0% in patients with elective neck control via irradiation .…”

Section: Discussionmentioning

confidence: 99%

“…12 Although Kim et al report a 13.5% risk of occult metastasis in patients who did not receive END at the time of primary resection, Dubal et al demonstrate that the risk could be as high as 22.2% in MS-SCC, which would meet the criteria for the employment of END. 8,21 Additionally, Le et al report a 20% 60month nodal relapse rate in patients without elective neck control versus 0% in patients with elective neck control via irradiation. 22 In the first large randomized controlled clinical trial of END in cancers of the buccal mucosa, tongue, and floor of mouth, D'Cruz et al found an absolute overall survival benefit of 12.5 percentage points and a disease-free survival benefit of 23.6 percentage points in those who underwent an END over observation.…”

Section: Discussionmentioning

confidence: 99%

“…The incidence rate of these metastases had widely been considered to be low in MS‐SCC due to the lack of an extensive lymphatic network in the area. However, recent studies show that the incidence may be as high as 22.2% . This rate would suggest a role for elective neck dissection (END) in the treatment of MS‐SCC.…”

Section: Introductionmentioning

confidence: 99%

“…However, recent studies show that the incidence may be as high as 22.2%. 8 This rate would suggest a role for elective neck dissection (END) in the treatment of MS-SCC.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The role of elective neck dissection in the treatment of maxillary sinus squamous cell carcinoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…However, recent studies show that the incidence may be as high as 22.2%. 8 This rate would suggest a role for elective neck dissection (END) in the treatment of MS-SCC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The role of elective neck dissection in the treatment of maxillary sinus squamous cell carcinoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…According to the literature from other countries, the survival rates of patients with carcinoma of the nasal cavity and paranasal sinus are not high, with 5-year survival rates of only 36.9-52% (4,12) and 5-year survival rates for patients with locally advanced disease of only 12-40% (13-15). Even with major surgery involving ocular evisceration with extensive range and damage, long-term survival rates are still as low as only 23-59% (13,(16)(17)(18). Fortunately, due to the intervention of chemotherapy, including ICT and CCRT, the 5-year OS of patients with squamous cell carcinoma of the nasal sinus has reached 59-76% in recent years (10,(19)(20)(21).…”

Section: Discussionmentioning

confidence: 99%

A clinical study of multimodal treatment for orbital organ preservation in locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinus

Nan-xiang

Chen

Wang

et al. 2016

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: This study aimed to investigate the efficacy of induction chemotherapy followed by concurrent chemotherapy and helical tomotherapy in patients with T4b squamous cell carcinoma of the nasal cavity and paranasal sinus in regard to orbital organ preservation and quality of life. Methods: Clinical data of 28 cases of patients with orbital involvement of T4b squamous cell carcinoma of the nasal cavity and paranasal sinus who received multimodal treatment for orbital organ preservation between May 2008 and September 2015 were retrospectively analysed. The treatment efficacy and side effects were assessed. The study included 18 male and 10 female patients. All patients were treated with induction chemotherapy followed by concurrent chemoradiotherapy and/or epidermal growth factor receptor inhibitor. Helical tomotherapy was applied as radiotherapy. Adverse reactions to the chemotherapy were assessed according to Common Terminology Criteria for Adverse Events, Version 4. The overall survival rate, local control rate and rate of effective orbital preservation were calculated using the Kaplan-Meier method. Results: All patients completed the planned chemotherapy, and 27 (96.4%) of the patients completed the planned radiotherapy cycle. After the multimodal treatment, the 3-year overall survival, local control rate and rate of effective orbital preservation of the patients were 59.2%, 80.2% and 77.8%, respectively. Conclusions: Multimodal treatment could preserve the orbital organs of patients with T4b squamous cell carcinoma of the nasal cavity and paranasal sinus, achieve relatively ideal organ protection and survival rates and improve the quality of life of patients with advanced squamous cell carcinoma of the nasal cavity and paranasal sinus, thus providing a new treatment option for these patients.

show abstract

Survival Outcomes of De Novo vs Inverted Papilloma–Associated Sinonasal Squamous Cell Carcinoma

Lee

Peterson

Embry

et al. 2021

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

IMPORTANCE Overall, the prognosis of sinonasal squamous cell carcinoma (SCC) is poor. This malignancy can arise de novo or from inverted papillomas, but it is unclear whether survival differences between the 2 pathologies exist.OBJECTIVE To assess for survival differences between patients with sinonasal de novo SCC (dnSCC) and those with inverted papilloma-associated SCC (IPSCC).DATA SOURCES A search of Ovid MEDLINE, Embase, Scopus, and the Cochrane Library from inception to January 23, 2020, with cross-referencing of retrieved studies, was performed. Additional data were requested from authors.STUDY SELECTION Inclusion and exclusion criteria were designed to capture studies with survival outcomes of adults with sinonasal SCC who underwent regular treatment. Clinical trials, cohort studies, case-control studies, and case series with more than 10 adults aged 18 years or older with sinonasal SCC were included. Exclusion criteria were studies on non-SCC sinonasal neoplasms, studies without histopathologic diagnoses, non-English language articles, nonhuman animal studies, and abstract-only articles. Two blinded investigators (J.J.L., A.M.P., T.W.E., or N.S.W.) screened each abstract and full text, and a third investigator (J.J.L. or P.P.) adjudicated discrepancies. Of 729 unique citations, 26 studies of 1194 total patients were included.DATA EXTRACTION AND SYNTHESIS Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines were followed. The Methodological Index for Nonrandomized Studies (MINORS) criteria were used to assess study quality. Two blinded investigators (J.J.L., A.M.P., T.W.E., or N.S.W.) independently extracted data from each study. Data were pooled using a random-effects model. MAIN OUTCOMES AND MEASURESThe primary outcome was overall survival, and secondary outcomes were disease-free and disease-specific survival. Before data collection, it was hypothesized that the dnSCC cohort would have worse survival outcomes than the IPSCC cohort. RESULTSOne study of patients with dnSCC, 12 studies of patients with IPSCC, and 5 studies with both cohorts were included in the meta-analysis of overall survival. The pooled 5-year overall survival rate for 255 patients with dnSCC was 56% (95% CI, 41%-71%; I 2 = 83.8%) and for 475 patients with IPSCC was 65% (95% CI, 56%-73%; I 2 = 75.7%). Five comparative studies of both cohorts totaling 240 patients with dnSCC and 155 patients with IPSCC were included in another meta-analysis. The pooled overall survival hazard ratio was 1.87 (95% CI, 1.24-2.84; I 2 = 0%).CONCLUSIONS AND RELEVANCE This systematic review and meta-analysis found that patients with dnSCC had almost a 2-fold increased risk of mortality compared with those with IPSCC. Large, multicenter studies are necessary to validate these findings before considering treatment alterations such as de-escalation based on histopathology.

show abstract

Squamous cell carcinoma of the maxillary sinus: A population‐based analysis

Abstract: 4.

Cited by 62 publications

References 44 publications

The role of elective neck dissection in the treatment of maxillary sinus squamous cell carcinoma

The role of elective neck dissection in the treatment of maxillary sinus squamous cell carcinoma

A clinical study of multimodal treatment for orbital organ preservation in locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinus

Survival Outcomes of De Novo vs Inverted Papilloma–Associated Sinonasal Squamous Cell Carcinoma

Contact Info

Product

Resources

About